Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Occupancy Rate, Revenue per Bed. Risks: Bed Count. Risk-adjusted uplift: $101.8M (vs $140.7M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $53.5M | $53.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $51.5M | $1.5M | $53.0M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $8.2M | $24.3M | $32.6M | $102.6M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $1.7M | $1.7M | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 32.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $13.4M | $26.8M | $40.1M | $53.5M | $53.5M | $53.5M | $53.5M |
| Denial Rate Reduction | $0 | $13.2M | $26.5M | $39.7M | $53.0M | $53.0M | $53.0M | $53.0M |
| A/R Days Reduction | $0 | $10.9M | $21.7M | $32.6M | $32.6M | $32.6M | $32.6M | $32.6M |
| Clean Claim Rate | $0 | $856K | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M |
| Cumulative | $0 | $38.3M | $76.7M | $114.1M | $140.7M | $140.7M | $140.7M | $140.7M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $140.7M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 76% / 17.1x | 81% / 19.4x | 85% / 21.6x | 87% / 22.8x | 89% / 23.9x |
| 9.0x | 72% / 14.9x | 76% / 16.9x | 80% / 18.9x | 82% / 19.9x | 84% / 20.9x |
| 10.0x | 67% / 13.1x | 72% / 14.9x | 76% / 16.7x | 77% / 17.6x | 79% / 18.5x |
| 11.0x | 63% / 11.6x | 68% / 13.2x | 72% / 14.9x | 73% / 15.7x | 75% / 16.5x |
| 12.0x | 60% / 10.3x | 64% / 11.8x | 68% / 13.3x | 70% / 14.1x | 72% / 14.9x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 50% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.2x, adding 5.2 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $86.5M | — | $86.5M | 3.2% |
| Year 1 | $89.1M | +$93.8M | $182.9M | 6.8% |
| Year 2 | $91.8M | +$140.7M | $232.5M | 8.7% |
| Year 3 | $94.5M | +$140.7M | $235.3M | 8.8% |
| Year 4 | $97.4M | +$140.7M | $238.1M | 8.9% |
| Year 5 | $100.3M | +$140.7M | $241.0M | 9.0% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $26.8M | $40.1M | $53.5M | $64.2M |
| Denial Rate Reductio | $26.5M | $39.7M | $53.0M | $63.6M |
| A/R Days Reduction | $16.3M | $24.4M | $32.6M | $39.1M |
| Clean Claim Rate | $856K | $1.3M | $1.7M | $2.1M |
| Total | $70.4M | $105.6M | $140.7M | $168.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 8 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 3.2% | -21.7% | -10.2% | 0.7% | P88 |
| Net-to-Gross | 34.0% | 25.0% | 31.1% | 50.5% | P62 |
| Occupancy | 80.2% | 61.4% | 67.5% | 78.4% | P75 |
| Rev/Bed | $4.2M | $893K | $1.5M | $2.2M | P88 |
| Exp/Bed | $4.0M | $1.0M | $1.6M | $2.2M | P88 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.